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The Notch signaling pathway is activated in the majority of T cell acute lymphoblastic leukemias (T-ALL).
Adding to the complexity of Notch signaling in hematopoiesis, recently in Nature, Klinakis et al. (2011)
demonstrate a tumor-suppressor function for the Notch pathway in myeloid malignancy.In hematopoiesis, Notch1 has an essential
role in T lymphocyte development. Acti-
vating mutations in Notch1 result in T-ALL
(Weng et al., 2004). However, the impor-
tanceof theNotch family in regulatingother
hematopoietic cell lineages, including
hematopoietic stem cells (HSCs), remains
controversial. There are four distinct Notch
receptors inmammals,making it difficult to
study the roles of Notch in hematopoiesis,
due to potential redundancy between the
receptors, even in compound conditional
knockout mutants.
Notchsignaling regulates the functionof
transcription factors of theCBF1/RBP-Jk,
Suppressor of Hairless, LAG1 (CSL) family
(Lai, 2004). When a Notch receptor is unli-
ganded, CSL familymembers act as core-
pressors of gene transcription (Figure 1A).
Upon binding of a Notch receptor to
a Notch ligand, a number of different
proteases sequentially cleave the Notch
receptor: ADAM metalloproteases cleave
the ligand-boundNotch receptor extracel-
lularly, creating a membrane-bound inter-
mediate, which is a substrate for gamma-
secretase (gSE, Figure 1B) (Kopan and Ila-
gan, 2009). gSE cleaves the intramem-
brane form of the Notch intracellular
domain (NICD), allowing it to translocate
to the nucleus to bind CSL, Mastermind
(MAM), and other coactivators, resulting
in activation of gene transcription of target
genes such as Hes1 (Figure 1C) (Kopan
and Ilagan, 2009).
gSE consists of four conserved compo-
nents: presenilin enhancer 2 (Pen-2), pre-
senilin (PS), nicastrin (Ncstn), and anterior
pharynx-defective 1 (Aph-1) (Figure 1B)
(Laudon et al., 2007). Pen-2, PS, and
Aph-1 are all transmembrane proteins,
whereas Ncstn has both an extracellular
and a transmembrane domain. Ncstn has
been demonstrated to have two func-
tions: (1) the extracellular domain binds602 Cell Stem Cell 8, June 3, 2011 ª2011 Elsto membrane-bound intermediate gSE
substrates such as those generated by
ADAM cleavage of ligand-bound Notch
and (2) the transmembrane domain is
required to interact with other members
of the gSE complex to allow it to move
from the endoplasmic reticulum to the
cell surface (De Strooper, 2005).
In their current study, Klinakis et al.
(2011) generated a conditional Nicastrin
allele (Ncstnfl/fl) that they crossed with
Mx1-Cre or Vav-Cre transgenic mice to
generate hematopoietic Ncstn knockout
mice (designated hereafter as Ncstn/)
(Klinakis et al., 2011). Both Ncstn/
strains produced identical phenotypes:
they rapidly developed increased num-
bers of white cells (leukocytes) in the
peripheral blood, spleen, and liver and
died by 20 weeks of age. The hematopoi-
etic cell phenotype present in both of the
Ncstn/ strains was reminiscent of
human chronic myelomonocytic leukemia
(CMML), and bone marrow transplant
studies showed that this hematopoietic
disease was cell-autonomous.
Increased numbers of myeloid-biased
Lineageneg, Sca-1+c-Kit+ (LSK) CD150+
CD48+ cells were observed in Ncstn/
BM.Thiswasaccompaniedbyasignificant
reduction in the frequency of lymphoid-
biased multipotent progenitor cells
(MPPs). There were also significantly
reduced numbers of megakaryocyte/
erythroid progenitors (MEPs) in the
Ncstn/ BM, accompanied by increases
in the numbers of granulocyte/monocyte
progenitors (GMPs) in bothBMandspleen.
The impact of loss of Ncstn on HSCs was
less clear, and would be difficult to ascer-
tain in thismodel, as the cancer phenotype
could complicate interpretation of the data.
However, the numbers of cells with
a phenotype most consistent with HSCs
(LSK CD150+CD48) were the same inevier Inc.Ncstn/ and WT BM. Collectively, these
data suggest that Ncstn (and, in turn, any
pathway it regulates) may not play an
important role in regulating HSC numbers,
but does have an active role in lineage-
fate commitment.
Consistent with the increased numbers
of myeloid-biased immature progenitors
observed in vivo, increased numbers of
granulocyte/macrophage and, in partic-
ular, macrophage colonies, were formed
from LSK cells from Ncstn/ mice
compared to WT mice. The Ncstn/
colonies had enhanced serial replating
potential compared to those obtained
from WT BM and GMPs. Furthermore,
whole transcriptome profiling of Ncstn/
GMPs revealed upregulation of several
members of a core leukemic self-renewal
signature defined by Krivtsov et al., 2006;
in particular, Hoxa family members.
Although gSE participates in cleaving
a number of different substrates, espe-
cially the amyloid precursor protein, the
authors focused on the Notch pathway,
since Ncstn/ mice exhibit known
Notch/ phenotypes, including a block in
T lymphocyte differentiation. To prove this
connection, they generated Notch1, -2,
and -3 compound null mutants (Mx1-
cre+N1f/fN2f/fN3). These mice phenocop-
ied the hematopoietic defects observed
in Ncstn/ mice, and deletion of both
Notch1 and Notch2 were sufficient to
recapitulate the phenotype.
To determine the underlying mecha-
nisms for the CMML-like disease observed
in Ncstn/ mice, the authors performed
transcriptome analysis of LSK and GMP
populations from WT and Mx1-Cre+
Ncstnf/f BM. This showed that a myeloid
gene-expression program was initiated in
Ncstn/ LSK cells as early as the CD150+
HSC stage of differentiation and persisted













































Figure 1. A Simplified Schematic Diagram of Notch Signaling and the
gSE Complex in Immature Hematopoietic Progenitor Cells
(A) When the Notch receptor is unliganded, CSL is bound to a corepressor, and
gene transcription is repressed.
(B) Essential components of the gSE protease are Ncstn, Pen-2, PS, and Aph-
1. The complex is active in WT cells (green). In Ncstn knockout cells (orange),
gSE complex is inactive.
(C) InWT cells, when the Notch receptor is liganded, an ADAMmetalloprotease
cleaves the extracellular portion of the Notch receptor, forming a membrane-
bound intermediate, which is then cleaved by gSE. The resulting NICD then
translocates to the nucleus, where it binds with CSL, MAM, and other coacti-
vators to activate transcription of genes, including Hes1. Hes1 represses genes
involved inmyeloid commitment, including Pu.1 andCepba, resulting in normal
differentiation of the immature progenitor cell.
(D) In Ncstn/ cells, gSE cannot recognize the Notch receptor intermediate
substrate and likely remains in the endoplasmic reticulum (ER). Hence, in li-
ganded form, the Notch receptor cannot be cleaved accurately and NICD
remains bound to the cell membrane, unable to translocate to the nucleus.
Gene transcription of Notch pathway targets therefore remains repressed,
target genes of Hes1 such as Pu.1 and Cepba are elevated in immature
progenitor cells, and CMML-like disease occurs.
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expression in LSK cells that
overexpressed Notch1 intra-
cellular fragment (Notch1IC
LSK, generated using Mx1-
Cre+ Ef1a1-Notch1IC mice)
inversely correlated with that
observed in Ncstn/ LSK.
Of note, expression of the
Notch target gene, Hes1,
was downregulated in
Ncstn/ LSK and upregu-
lated in Notch1IC LSK. Hes1
is a transcriptional repressor;
hence, the authors hypothe-
sized that Hes1 could be
responsible for the sup-
pressive effects of Notch
signaling on GMP-specific
gene expression. Hes1 over-
expression in c-Kit+ progeni-
tors from WT and Ncstn/
BM shifted the differentiation
of these cells from granulo-
cytic (Gr-1+) cells into mega-
karyocytic (CD41+) cells after
7 days in methylcellulose,
although increased numbers
of Gr-1+ cells were still
observed in Ncstn/ BM
that overexpressed Hes1




of key GM-lineage com-
mitment genes such as Pu.1
and Cebpa in WT LSK cells
due to direct binding of Hes1
on their promoters.
Given the striking pheno-
typic resemblanceofNcstn/
hematopoiesis to that of
human CMML (Figure 1D),
the authors sequenced gSE/
Notch-pathway genes in
human CMML samples and
Lai, E.C. (2004identified novel loss-of-function mutations
in a subset of these samples. These
mutations includedNcstn, another compo-
nent of the gSE complex, Aph-1, and
Notch-pathway-specific members MAM-
like protein 1 (MAML1) and NOTCH2.
Importantly, Notch-pathway mutations
were restricted to CMML samples and
were not found in other types of myelopro-
liferative disorders. These mutations were
detectedalongwithothermutations known
to be involved inmyeloid leukemia, such asJAK2,KRAS, and TET2. Thus,mutations in
the Notch pathway may act cooperatively
withother oncogenicpathways in the initia-
tion and maintenance of CMML.
It is worth noting, however, that the
phenotype of myeloproliferative disease
in Ncstn/ and Mx1-cre+N1f/fN2f/fN3
mice was not detected in either CSL/
Rbp-Jk/ mice or mice transplanted
with BM overexpressing dominant-nega-
tive MAML (Han et al., 2002; Maillard
et al., 2008). As theCSL signaling pathwayCell Stem Cell 8, June 3,is downstream of both Ncstn
and Notch, it raises the possi-
bility that a CSL-independent
pathway may be involved
(Sanalkumar et al., 2010).
The results of Klinakis et al.
(2011) expand the repertoire
of the Notch pathway in
cancer and demonstrate that
it can act as both an onco-
genic and tumor-suppressor
pathway, depending on the
cell lineage affected and the
nature of the mutation. The
study further highlights the
utility of murine models in ex-
panding our understanding of
humancancer genetics and in
providing critical insights into
gene function that can be of
direct relevance to our under-
standing of human disease.
Finally, it implicates that ther-
apeutic modulation of the
Notch pathway in hematopoi-
etic diseases may be
a double-edged sword.
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